+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Hyperkalemia Drugs Market 2019-2023 - Product Image

Global Hyperkalemia Drugs Market 2019-2023

  • ID: 4721389
  • Report
  • December 2018
  • Region: Global
  • 106 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Ardelyx
  • AstraZeneca
  • Perrigo
  • Sanofi
  • Vifor Pharma
  • MORE
The growing cases of various chronic diseases such as chronic kidney diseases and cardiovascular-related disorders are driving the market growth. Chronic kidney diseases increase the risk of patient developing hyperkalemia significantly, as the kidneys lose the ability to excrete potassium through urine. The ability of kidneys to excrete potassium decreases with time, which increases the risk of hyperkalemia becoming acute. Similarly, cardiovascular-related disorders also increase the risk of hyperkalemiain people. Hence, the increasing prevalence of these diseases is expected to contribute heavily of the growth of the market during the forecast. The hyperkalemia drugs market will grow at a CAGR of more than 20% during the forecast period.

Market Overview

Increasing prevalence of hyperkalemia

The global hyperkalemia drugs market has witnessed a growth in recent years, primarily due to the increasing prevalence of the disease globally. The recurring nature of the disease is another factor that is expected to contribute to the huge unmet need globally. Due to the increasing prevalence and the huge unmet need, the market has witnessed the approval of novel drugs.

Lack of approved therapies

The treatment using these therapies is known to decrease the potassium levels in the blood only to a certain extent. Due to the presence of a limited number of approved therapies, the market has huge growth potential; however the pipeline for hyperkalemia is weak, with only two molecules bring studied currently. These molecules are in the pre-clinical stages of development and are not expected to enter the market during the forecast period.

For the detailed list of factors that will drive and challenge the growth of the hyperkalemia drugs market during the 2019-2023, view this report.

Competitive Landscape

The global hyperkalemia drugs market is extremely concentrated. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.’
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Ardelyx
  • AstraZeneca
  • Perrigo
  • Sanofi
  • Vifor Pharma
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT
  • Preface
  • Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
PART 04: MARKET SIZING
  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 06: MARKET SEGMENTATION BY TYPE
  • Market segmentation by type
  • Comparison by type
  • Chronic hyperkalemia - Market size and forecast 2018-2023
  • Acute hyperkalemia - Market size and forecast 2018-2023
  • Market opportunity by type
PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE
  • Geographic segmentation
  • Geographic comparison
  • Americas - Market size and forecast 2018-2023
  • EMEA - Market size and forecast 2018-2023
  • APAC - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity
PART 09: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 10: MARKET TRENDS

PART 11: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
  • Competitive scenario
PART 12: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Ardelyx
  • AstraZeneca
  • Perrigo
  • Sanofi
  • Vifor Pharma
PART 13: APPENDIX
  • Research methodology
  • List of abbreviations
List of Exhibits
Exhibit 01: Years in consideration
Exhibit 02: Global urological disorder drugs market
Exhibit 03: Segments of global urological disorder drugs market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2018
Exhibit 18: Type - Market share 2018-2023 (%)
Exhibit 19: Comparison by type
Exhibit 20: Chronic hyperkalemia - Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Chronic hyperkalemia - Year-over-year growth 2019-2023 (%)
Exhibit 22: Acute hyperkalemia - Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Acute hyperkalemia - Year-over-year growth 2019-2023 (%)
Exhibit 24: Market opportunity by type
Exhibit 25: Customer landscape
Exhibit 26: Market share by geography 2018-2023 (%)
Exhibit 27: Geographic comparison
Exhibit 28: Americas - Market size and forecast 2018-2023 ($ millions)
Exhibit 29: Americas - Year-over-year growth 2019-2023 (%)
Exhibit 30: EMEA - Market size and forecast 2018-2023 ($ millions)
Exhibit 31: EMEA - Year-over-year growth 2019-2023 (%)
Exhibit 32: APAC - Market size and forecast 2018-2023 ($ millions)
Exhibit 33: APAC - Year-over-year growth 2019-2023 (%)
Exhibit 34: Key leading countries
Exhibit 35: Market opportunity
Exhibit 36: Decision framework
Exhibit 37: Impact of drivers and challenges
Exhibit 38: Vendor landscape
Exhibit 39: Landscape disruption
Exhibit 40: Vendors covered
Exhibit 41: Vendor classification
Exhibit 42: Market positioning of vendors
Exhibit 43: Ardelyx - Vendor overview
Exhibit 44: Ardelyx - Business segments
Exhibit 45: Ardelyx - Organizational developments
Exhibit 46: Ardelyx - Geographic focus
Exhibit 47: Ardelyx - Key offerings
Exhibit 48: Ardelyx - Key customers
Exhibit 49: AstraZeneca - Vendor overview
Exhibit 50: AstraZeneca - Business segments
Exhibit 51: AstraZeneca - Organizational developments
Exhibit 52: AstraZeneca - Geographic focus
Exhibit 53: AstraZeneca - Key offerings
Exhibit 54: AstraZeneca - Key customers
Exhibit 55: Perrigo - Vendor overview
Exhibit 56: Perrigo - Business segments
Exhibit 57: Perrigo - Organizational developments
Exhibit 58: Perrigo - Geographic focus
Exhibit 59: Perrigo - Segment focus
Exhibit 60: Perrigo - Key offerings
Exhibit 61: Perrigo - Key customers
Exhibit 62: Sanofi - Vendor overview
Exhibit 63: Sanofi - Business segments
Exhibit 64: Sanofi - Organizational developments
Exhibit 65: Sanofi - Geographic focus
Exhibit 66: Sanofi - Segment focus
Exhibit 67: Sanofi - Key offerings
Exhibit 68: Sanofi - Key customers
Exhibit 69: Vifor Pharma - Vendor overview
Exhibit 70: Vifor Pharma - Business segments
Exhibit 71: Vifor Pharma - Organizational developments
Exhibit 72: Vifor Pharma - Geographic focus
Exhibit 73: Vifor Pharma - Key offerings
Exhibit 74: Vifor Pharma - Key customers
Exhibit 75: Validation techniques employed for market sizing
Exhibit 76: List of abbreviations
Note: Product cover images may vary from those shown
3 of 5

FEATURED COMPANIES

  • Ardelyx
  • AstraZeneca
  • Perrigo
  • Sanofi
  • Vifor Pharma
  • MORE
Global Hyperkalemia Drugs Market 2019-2023

The analyst recognizes the following companies as the key players in the global hyperkalemia drugs market: Ardelyx, AstraZeneca, Perrigo, Sanofi, Vifor Pharma.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the strategic alliances help the companies to increase their market share, thereby driving the overall market growth.”

According to the report, one of the major drivers for this market is the rapidly increasing investments in the increasing prevalence f these diseases is expected to contribute heavily to the growth of the market during our forecast period.

Further, the report states that one of the major factors hindering the growth of this market is the poor diagnosis of the disease which will hinder the growth of the market during the forecast period.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
4 of 5
  • Ardelyx
  • AstraZeneca
  • Perrigo
  • Sanofi
  • Vifor Pharma
Note: Product cover images may vary from those shown
5 of 5

Loading
LOADING...

Adroll
adroll